Renal

**Localized**
- T1b or greater (has not spread beyond the kidney)
  - IRB#16576 Atezolizumab vs placebo as adjuvant therapy following nephrectomy

**Clear Cell**
- No Prior Systemic Therapy
  - IRB# 16300 Merck 3475
- Metastectomy Candidate
  - IRB#9241 Pazopanib vs. Placebo in Patients with mRCC
- Cytoreductive Nephrectomy Candidate
  - No trials Currently Available

**Non-Clear Cell**
- Prior Systemic Therapy
  - IRB# 11283 A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone (Including a Lead-In Phase IB Dose-Escalation Portion) in Patients With Advanced Or Metastatic Renal Cell Carcinoma.

**Metastatic/advanced**
- No Trials Currently Available

Additional Information:
- IRB# 16085 S1500 – Cabozantinib, Crizotinib, Savolitinib and sunitinib

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

2/17/17